Agenus Inc (AGEN): Garo H Armen , CEO of Agenus Inc purchased 100,000 shares on May 6, 2016. The Insider buying transaction was reported by the company on May 10, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.18 per share for a total value of $317,895.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 10, 2016, Garo H Armen (CEO) purchased 100,000 shares at $3.18 per share price.On May 9, 2016, Ozer Baysal (Chief Business Officer) purchased 2,250 shares at $3.10 per share price.Also, On Sep 29, 2015, Charles Evan Ballantyne (CFO) purchased 10,000 shares at $5.05 per share price.On May 1, 2015, Shahzad Malik (director) sold 1,107,377 shares at $7.09 per share price.
Shares of Agenus Inc (AGEN) ended Friday, May 6, 2016 session in red amid volatile trading. The shares closed down -0.1 points or -3.22% at $3.01 with 14,74,527 shares getting traded. Post opening the session at $3.1, the shares hit an intraday low of $2.97 and an intraday high of $3.17 and the price vacillated in this range throughout the day. The company has a market cap of $260 M and the number of outstanding shares has been calculated to be 8,65,16,484 shares. The 52-week high of Agenus Inc is $10.1599 and the 52-week low is $2.61.
Company has been under the radar of several Street Analysts.Agenus Inc is Upgraded by Maxim Group to Buy and the brokerage firm has set the Price Target at $7. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Mar 11, 2016.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform including Retrocyte Display technology which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines and its saponin-based vaccine adjuvants QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages including a series of CPMs in investigational new drug (IND)-enabling studies Prophage Series vaccine a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM) which is a form of brain cancer and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner GlaxoSmithKline (GSK).